Oppenheimer lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $10 and keeps an Outperform rating on the shares following quarterly results. The most notable update was that ALPHA3’s first update is being pushed back 6 months. Management said that sites were taking longer to recruit patients than anticipated-and they took full responsibility for it, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target lowered to $9 from $12 at Baird
- Buy Rating Affirmed for Allogene Therapeutics Amid Strategic Developments and Financial Strength
- Allogene Therapeutics price target lowered to $7 from $9 at Piper Sandler
- Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
- Allogene downgraded to Market Perform from Outperform at Citizens JMP